Physician profile
Ki Wan Kim
NPI 1356490734
$6,156.04
in general payments reported to CMS, 2019-2025
50 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $675 · 2021: $1,153 · 2022: $900 · 2023: $1,159 · 2024: $1,063 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,159.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $613.46 | 2019-2025 | Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $489.80 | 2020-2025 | Keytruda, Keytruda Qlex, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $427.31 | 2020-2025 | Opdivo |
| Daiichi Sankyo INC. | $394.07 | 2020-2025 | Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $377.20 | 2021-2025 | Libtayo |
| Seagen INC. | $289.61 | 2020-2023 | Tukysa, Tivdak |
| Intuitive Surgical, INC. | $229.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $226.09 | 2020-2023 | Shingrix |
| Ambu INC. | $202.84 | 2021-2022 | |
| Janssen Biotech, INC. | $195.05 | 2020-2025 | Rybrevant |
| Davol INC. | $193.44 | 2024-2025 | Phasix Mesh, Arista |
| On Target Laboratories, INC | $182.06 | 2025 | Cytalux |
| Jazz Pharmaceuticals INC. | $163.35 | 2021-2024 | |
| Galvanize Therapeutics, INC | $149.27 | 2023 | Aliya System |
| Genentech USA, INC. | $133.10 | 2023-2024 | Tecentriq, Alecensa, Gavreto |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ki Wan Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.